ChromaDex (NASDAQ:CDXC) Trading Down 5.5% – Should You Sell?

ChromaDex Co. (NASDAQ:CDXC) traded down 5.5% during trading on Friday . The stock traded as low as $7.15 and last traded at $7.21. 374,121 shares were traded during mid-day trading, a decline of 30% from the average session volume of 537,406 shares. The stock had previously closed at $7.63.

Analyst Ratings Changes

A number of brokerages have issued reports on CDXC. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Roth Mkm raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th.

ChromaDex Price Performance

The firm has a market capitalization of $568.27 million, a P/E ratio of 744.74 and a beta of 1.88. The firm’s fifty day moving average price is $4.61 and its 200-day moving average price is $3.59.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period last year, the firm earned ($0.01) EPS. Analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On ChromaDex

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of ChromaDex by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after purchasing an additional 17,963 shares during the last quarter. State Street Corp boosted its holdings in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after buying an additional 62,692 shares in the last quarter. Renaissance Technologies LLC grew its position in ChromaDex by 8.4% in the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock worth $1,136,000 after buying an additional 32,400 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of ChromaDex in the second quarter valued at $597,000. Finally, Bank of New York Mellon Corp lifted its position in shares of ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after acquiring an additional 119,915 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.